[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.141.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
November 5, 2008

The Challenges of Epidemiologic Research in Non-Hodgkin Lymphoma

Author Affiliations

Author Affiliations: Division of Hematology/Oncology, Department of Medicine (Dr Evens), The Robert H. Lurie Comprehensive Cancer Center (Drs Evens and Chiu), and Department of Preventive Medicine (Dr Chiu), Northwestern University Feinberg School of Medicine, Chicago, Illinois.

JAMA. 2008;300(17):2059-2061. doi:10.1001/jama.2008.589

The incidence of non-Hodgkin lymphoma (NHL) increased by more than 80% between 1975 and 1991 in the United States, representing one of the largest increases of any cancer.1 While the overall NHL incidence rates began to stabilize in the late 1990s, the temporal trends varied by histologic subtype with the incidence of T/NK [natural killer]–cell lymphomas increasing 4% per year during 1992-2001 compared with 0.5% per year for B-cell lymphoma.2 Part of the overall steep increase in NHL incidence over the last several decades is due to human immunodeficiency virus (HIV) infection, although the incidence of NHL has been increasing irrespective of HIV status.3 Other pathogenic associations with NHL include viruses and bacteria (eg, human T-cell lymphotropic virus type 1,4 human herpesvirus 8,5 hepatitis C,6 and Helicobacter pylori7) and medications that cause extreme immunodeficiency. However, the etiology of NHL remains largely unknown. Furthermore, the significant geographic differences (eg, the incidence of NHL is 3-4 times more common in the United States vs Japan)8 and varying incidences by sex, age, and race in population registry data are unexplained.2,9

First Page Preview View Large
First page PDF preview
First page PDF preview
×